A survey of asbestos abatement projects performed by public agencies was undertaken for the County of Erie, Pennsylvania, USA. The time period for this survey was 1996 to November 1999. Project data collected included project name by public agency, name of contractor, quantity of work, cost for this work, and time period over which work was conducted. Initial information on projects was obtained from the Pennsylvania Department of Environmental Protection and was followed up through contact with the specific agency. Comparison of this survey with that of one previous during the time period of 1992–1994 suggests the amount of abatement in the public sector has decreased. Distribution of costs between bids was nonnormal and appears to best fit a logarithmic distribution. Some information was not available from the agencies, suggesting either a lack of understanding of environmental regulations or noncompliance. Information presented provides an insight into the direction of the asbestos abatement industry, its management, liabilities and future problems.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.